Loading clinical trials...

Acute Lymphoblastic Leukemia Registry at Asan Medical Center | Clinical Trials | Clareo Health

TERMINATED

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center

NCT01761682•Asan Medical Center

Summary

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed Description

1. Acquisition of informed concent form 2. Data acquisition from medical record including * demographic / disease-associated factors * details of treatment, and its results * complications during treatment * genetic data * survival outcome (upto 10 years) 3. Accumulation of data for 30 years 4. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Eligibility

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma)
•15 years of age and over
•All patients who give written consent according to guidelines at Asan Medical Center committee on human research

Exclusion Criteria

•Patients who refuse to give consent to registering

Locations (1)

Asan Medical Center

Seoul, South Korea

Key Dates

Start Date

January 1, 2013

Primary Completion Date

May 1, 2016

Completion Date

May 1, 2016

Last Updated

July 20, 2018

Enrollment

200

ACTUAL participants

Conditions

Leukemia, Acute LymphoblasticPrecursor B-Cell Lymphoblastic LeukemiaLeukemia, Biphenotypic, AcuteLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveLymphoblastic Lymphoma

Interventions

Diagnosed as ALL

OTHER

Newly-diagnosed Pediatric T-cell ALL Protocol

NCT06855810

Acute Lymphoblastic LeukemiaChildhood Leukemia, Acute Lymphoblastic+1 more

View study

RECRUITINGPHASE1/PHASE2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

NCT06880913

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 20, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Inclusion Criteria

Exclusion Criteria

Newly-diagnosed Pediatric T-cell ALL Protocol

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

COVID-19 and Childhood Cancer

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)